PTC Therapeutics, Inc. PTCT · Stock Open PTC Therapeutics, Inc. in new tab
PTC Therapeutics, Inc. Analysis (PTCT)
Is PTC Therapeutics, Inc. a good investment? PTC Therapeutics, Inc. (PTCT) is currently trading at 68.12 USD. Market analysts have a consensus price target of 96.07 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 7.60. This relatively low multiple may signal that PTC Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: PTC Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 2.74.
Investor FAQ
Does PTC Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is PTC Therapeutics, Inc.?
PTC Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -2.52.
Company Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Community Discussion